These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35252734)

  • 1. Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots.
    Pramanik A; Sharma PC; Patibandla S; Gao Y; Ruppa-Kasani V; Goli J; Kumar A; Chatterjee A; Sinha SS; Bates JT; Bierdeman MA; Tandon R; Ray PC
    ACS Omega; 2022 Mar; 7(9):8150-8157. PubMed ID: 35252734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections.
    Pramanik A; Mayer J; Sinha SS; Sharma PC; Patibandla S; Gao Y; Corby LR; Bates JT; Bierdeman MA; Tandon R; Seshadri R; Ray PC
    ACS Appl Bio Mater; 2022 Sep; ():. PubMed ID: 36053723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Design and Experimental Validation of ACE2-Derived Peptides as SARS-CoV-2 Receptor Binding Domain Inhibitors.
    Sarma S; Herrera SM; Xiao X; Hudalla GA; Hall CK
    J Phys Chem B; 2022 Oct; 126(41):8129-8139. PubMed ID: 36219223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis.
    Khater I; Nassar A
    Inform Med Unlocked; 2022; 29():100873. PubMed ID: 35136832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity.
    Liu H; Wei P; Aviszus K; Zhang Q; Linderberger J; Yang J; Liu J; Chen Z; Waheed H; Reynoso L; Downey GP; Frankel SK; Kappler JW; Marrack P; Zhang G
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the transmission feasibility of SARS-CoV-2 Omicron (B.1.1.529) variant to 143 mammalian hosts: insights from S protein RBD and host ACE2 interaction studies.
    Samanta A; Alam SSM; Ali S; Hoque M
    Funct Integr Genomics; 2023 Jan; 23(1):36. PubMed ID: 36631570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Structural Analysis of Human ACE2 Receptor with Spike Protein of SARS-CoV-2 Variants: Implications to Understand Infectivity of the Virus.
    Koley T; Goswami A; Kumar M; Upadhyay N; Hariprasad G
    Adv Appl Bioinform Chem; 2022; 15():21-27. PubMed ID: 35734581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus.
    Devaux CA; Fantini J
    Front Microbiol; 2023; 14():1199561. PubMed ID: 37520374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RBD spatial orientation of the spike protein and its binding to ACE2: insight into the high infectivity of the SARS-CoV-2 Delta variant from MD simulations.
    Lv N; Cao Z
    Phys Chem Chem Phys; 2022 Oct; 24(39):24155-24165. PubMed ID: 36168828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
    Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.